References
- GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–1724.
- Manolis AJ, Agabiti Rosei E, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens. 2012;30:239–252.
- Kjeldsen SE, Aksnes T, Wachtell K, et al. Arterial stiffness predicts incident atrial fibrillation in the Framingham heart study: a mechanistic contribution in people with high blood pressure or history of hypertension. Hypertension. 2016;68:555–557.
- Hohnloser SH, Crijns HJ, van Eickels M, for the ATHENA Investigators, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–678.
- The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–2078.
- Connolly SJ, Ezekowitz MD, Yusuf S, for the RE-LY steering committee and iinvestigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
- Patel MR, Mahaffey KW, Garg J, for the ROCKET steering committee and investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
- Connolly SJ, Eikelboom J, Joyner C, for the AVERROES steering committee and investigators, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.
- Estruch R, Ros E, Salas-Salvadó J, for the PREDIMED Study Investigators, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290.
- Sabatine MS, Giugliano RP, Keech AC, for the FOURIER Steering Committee and Investigators, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
- Cuspidi C, Sala C, Tadic M, et al. Untreated masked hypertension and subclinical cardiac damage: a systematic review and meta-analysis. Am J Hypertens. 2015;28:806–813.
- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J. 2009;338:b1665.
- Thomopoulosa C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2305–2314.
- Kjeldsen SE, Oparil S, Narkiewicz K, et al. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press. 2016;25:1–3.